Pfizer Exec Says Co's Research And Development In Oncology Remains Unchanged By Cost-Cut Program; Starting Negotiations With Payers On U.S. Commercial Prices For Covid Treatment Paxlovid
Portfolio Pulse from Benzinga Newsdesk
Pfizer's research and development in oncology will not be affected by the company's cost-cutting program. The company is also starting negotiations with payers on U.S. commercial prices for its Covid treatment, Paxlovid.
October 16, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Pfizer's cost-cutting program will not impact its oncology R&D. The company is negotiating U.S. prices for Paxlovid, its Covid treatment.
The news indicates that Pfizer's cost-cutting program will not affect its oncology research and development, which is positive for investors as it shows the company's commitment to this area. However, the impact of the negotiations on the U.S. prices for Paxlovid is uncertain at this stage, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100